- Open Access
Detecting primitive hematopoietic stem cells in total nucleated and mononuclear cell fractions from umbilical cord blood segments and units
© Patterson et al.; licensee BioMed Central. 2015
- Received: 5 December 2014
- Accepted: 11 February 2015
- Published: 18 March 2015
Rare hematopoietic stem cell populations are responsible for the transplantation engraftment process. Umbilical cord blood (UCB) is usually processed to the total nucleated cell (TNC), but not to the mononuclear cell (MNC) fraction. TNC counts are used to determine UCB unit storage, release for transplantation and correlation with time to engraftment. However, the TNC fraction contains varying concentrations of red blood cells, granulocytes, platelets and other cells that dilute and mask the stem cells from being detected. This does not allow the quality and potency of the stem cells to be reliably measured.
63 UCB segments and 10 UCB units plus segments were analyzed for the response of both primitive lympho-hematopoietic and primitive hematopoietic stem cells in both the TNC and MNC fractions. The samples were analyzed using a highly sensitive, standardized and validated adenosine triphosphate (ATP) bioluminescence stem cell proliferation assay verified against the colony-forming unit (CFU) assay. Dye exclusion and metabolic viability were also determined.
Regardless of whether the cells were derived from a segment or unit, the TNC fraction always produced a significantly lower and more variable stem cell response than that derived from the MNC fraction. Routine dye exclusion cell viability did not correspond with metabolic viability and stem cell response. Paired UCB segments produced highly variable results, and the UCB segment did not produce similar results to the unit.
The TNC fraction underestimates the ability and capacity of the stem cells in both the UCB segment and unit and therefore provides an erroneous interpretation of the of the results. Dye exclusion viability can result in false positive values, when in fact the stem cells may be dead or incapable of proliferation. The difference in response between the segment and unit calls into question the ability to use the segment as a representative sample of the UCB unit. It is apparent that present UCB processing and testing methods are inadequate to properly determine the quality and potency of the unit for release and use in a patient.
- Colony-forming unit
- ATP bioluminescence
- Proliferation assay
- Umbilical cord blood
- Stem cell transplantation
- Total nucleated cell fraction
- Stem cell processing
- Umbilical cord blood unit
Hematopoietic stem cell transplantation using bone marrow, mobilized peripheral blood or umbilical cord blood (UCB) as stem cell sources, are routine clinical procedures. Yet the presence and functionality of the stem cells is mostly assumed, rather than actually measured. The methylcellulose colony-forming unit (CFU) assay has been used to detect many different cell populations from stem cells with high proliferative potential [1-4] to precursor cells that demonstrate few cell divisions [5,6]. Although the assay is not routinely used in bone marrow or mobilized peripheral blood stem cell transplantation processing , a functional assay is routinely required for cord blood processing, since UCB units are cryopreserved and engraftment occurs later than that for bone marrow or mobilized peripheral blood [8,9]. However, rather than detecting stem cells, the CFU assay is usually employed to detect granulocyte-macrophage (GM) progenitor cells as an indicator of time to neutrophil engraftment . With the exception of CD34 enumeration, which became routine in the early 1990s , the CFU assay together with total nucleated cell (TNC) counts and viability represent the three basic tests that have been continuously used to characterize UCB cells for storage and transplantation purposes since the first UCB transplant in 1988 .
Since its introduction in 1966 for murine cells [13,14], and later for human bone marrow cells , counting colonies in a methylcellulose CFU assay has been the method of choice to determine primitive hematopoietic cell functionality. However, both clonal and liquid culture assays have been reported using an instrument-based MTT (3-(4,5-dimethylthiazol-2-yl)-2,5,-diphenyltetrazolium bromide) colorimetric readout, based on the reduction of the tetrozolium substrate by the mitochondria to a yellow formazan product. This provides a metabolic viability version of the CFU assay [16-18]. The ability to use an instrument-based, biochemical readout, such as MTT, laid the groundwork for combining the methylcellulose clonal CFU assay with an adenosine triphosphate (ATP) marker for measuring in vitro hematopoietic stem and progenitor cell proliferation ability. This was demonstrated in 2005 , and later used to evaluate umbilical cord blood progenitor cells .
Adenosine triphosphate is the cell’s source of chemical energy. It is produced in the mitochondria of cells. Hepatocytes and kidney cells for example, have inherently high levels of ATP associated with their high levels of metabolism. Other cells, such as quiescent stem cells, exhibit low levels of metabolism and therefore have low basal levels of ATP production. Cells require ATP for numerous biochemical reactions, from cellular respiration to DNA synthesis and cell division. During these reactions, ATP is reduced to adenosine di- (ADP) and monophosphate (AMP) and the high-energy phosphate atoms are recycled to produce more ATP. It follows that ATP is vital to the cell’s metabolism and health; cells that do not or cannot produce ATP are metabolically dead.
Crouch et al. introduced the use of ATP bioluminescence measurement for proliferating cells in 1993 . The reaction requires the addition of luciferin and the enzyme luciferase to produce oxyluciferin, which creates a bioluminescence signal that is measured as photons by a luminometer. To measure intracellular ATP (iATP) in cells, the ATP must be the limiting factor. The reaction also requires the presence of oxygen. Red blood cells (RBC), although they do not contain mitochondria, have both high levels of ATP and oxygen. If ATP is being used to measure cell proliferation in suspensions containing high concentrations of RBCs, the latter acts as an impurity in the cell preparation producing false positive results. Simply removing or reducing the RBCs can negate the problem. However, if the RBCs are lysed, the presence of hemoglobin can inhibit the ATP luciferin/luciferase reaction and cause low ATP concentrations. The presence of RBCs could therefore pose a problem to characterize rare stem cell populations in hematopoietic cell therapy products that use a total nucleated cell (TNC) fraction. This is because RBCs and other cell impurities, including granulocytes, platelets and other cell types, can be present in varying amounts depending on the processing method .
Although it was shown that UCB units could be processed by density gradient centrifugation to produce large numbers of mononuclear cells (MNCs) [23,24], the TNC fraction is the product of choice. It is more rapidly produced than the MNC fraction and is less costly. Over the years, the TNC and CFU counts, number of CD34+ cells and even viability have all been associated, to varying degrees, with clinical outcome [10,25,26]. In addition, these and especially TNC, are used as decision-making parameters to permanently store UCB units for transplantation purposes and select and release a unit for use in a patient.
One of the major hurdles in stem cell transplantation has been the standardization, optimization and validation of procedures and assays [27,28] required to produce a stem cell product that can be accurately and reliably characterized prior to use. Numerous articles have addressed issues such as processing procedures, cryopreservation techniques, pre-freeze and post-thaw methodologies. Nevertheless, viability, CD34, the CFU assay and clinical outcome are based on the TNC fraction. Therefore, despite the problems associated with a TNC fraction to detect and measure the presence of stem cells, we tested a “null hypothesis” by assuming that UCB segments and units did not have to be further purified in order to reliably and reproducibly measure stem cells in a standardized and validated assay. In short, measurement of UCB stem cells should not be dependent upon the purity of the UCB preparation. The results presented below reject that hypothesis and call into question UCB quality and potency based on the TNC fraction.
Umbilical cord blood samples
Umbilical cord blood sample segments used in this study were purchased from two different cord blood banks as cryopreserved research samples. Cord blood bank (CBB) 1 processed samples using Sepax technology (BioSafe America), while CBB 2 employed AXP technology (Cesca Therapeutics, formerly ThermoGenesis, Rancho Cordova, CA). In addition, individual units with attached segments were also obtained. No pre-freeze samples were available for these studies. Donors gave their consent for the cells to be used for research purposes. The segment volume ranged from 0.2 mL to less than 0.1 mL. The unit volumes were between 20 mL to 30 mL each.
Preparation of samples for use
Umbilical cord blood segments and units were both thawed in a 37°C water bath. After thawing a segment, a 1 mL syringe attached to a 22 gauge needle was used to puncture two holes in the top of the segment and the contents gently mixed before removing the cells. The volume was noted and the contents transferred to a 2 mL tube containing the same volume of Iscove’s Modified Dulbecco’s Medium (IMDM, Life Technologies). The contents were gently mixed, but a wash step was not performed. This would be a normal procedure if cells from a segment were tested, since the number of cells available would be reduced by a wash step. However, for some of the segments, a small volume was removed, without any additional treatment, to perform a differential cell count (Medonic CA620, Stockholm, Sweden), viability using 7-aminoactinomycin D (7-AAD) by flow cytometry (Accuri C6, BD Biosciences) and nucleated cell count (Z2 particle counter, Beckman Coulter). This post-thaw, unseparated fraction was designated the TNC fraction. The remaining cells were under-layered with 1.0 mL of NycoPrep 1.077 (Axis Shield, Oslo, Norway) density gradient medium and centrifuged according to the manufacturer’s instructions. The interface cells were removed and transferred to another tube. This separated cell fraction was designated the MNC fraction, which was resuspended in 2.0 mL of IMDM, centrifuged at 200 × g for 10 minutes at room temperature to wash the cells. The resulting cell pellet was resuspended in 0.2 mL of IMDM. A second nucleated cell count, viability, and for some samples, a differential cell count was performed. Umbilical cord blood units were handled and processed in exactly the same manner, except that the contents of the units were allowed to drain into a 50 mL tubed through one of the ports, mixed gently and aliquoted into 0.3 mL samples and transferred to 2 mL tubes for processing after several samples had been removed to obtain initial differential and nucleated cell counts and viability values. Each 0.3 mL aliquot was diluted with 0.3 mL of IMDM and fractionated using the same procedure as the segments.
Colony-Forming Unit (CFU) assay
A miniaturized CFU assay (CAMEO-4, HemoGenix, Colorado Springs, CO) was performed as previously described . The cell concentration was adjusted to 0.5 × 106 cells/mL and a 3-point cell dose response prepared to produce final concentrations. The total volume prepared was 0.6 mL, including cells. Using a positive displacement electronic pipette (Eppendorf, Hamburg, Germany), 0.1 mL was dispensed into 4 replicate wells in a 35 mm Petri dish, each with a growth surface area of 0.95 mm2. The cell population detected was the primitive hematopoietic stem cell or colony-forming unit – granulocyte, erythroid, macrophage, megakaryocyte (CFC-GEMM) stimulated with erythropoietin (EPO), granulocyte-macrophage colony stimulating factor (GM-CSF), thrombopoietin (TPO), stem cell factor (SCF), Flt-3 ligand and interleukins 3 and 6 (IL-3, IL-6). Cells were cultured in a 37°C humidified incubator gassed with 5% CO2 and 5% O2 . Colonies were manually counted using an inverted microscope (40 – 100× magnification, Zeiss, U.S.A.) after 9–10 days of incubation to ensure that the colonies do not grow together. This is a shorter incubation period than normal for CFU cultures (14–16 days) and is primarily due to a difference in methylcellulose culture reagent formulation and the smaller growth surface area than for a 35 mm Petri dish.
ATP Bioluminescence proliferation assay (assay performed in 96 plate)
Since the CFU assay cannot be used to directly measure the proliferation of stem cells, a 96-well plate, ATP bioluminescence assay was employed (HALO, HemoGenix, Colorado Springs, CO). This has been described in detail elsewhere [19,20,30]. In essence, when cells are stimulated to proliferate, their intracellular ATP concentrations increases several fold above the basal iATP level. The change in iATP concentrations directly correlates with the metabolic activity (viability) of the cells and their proliferation status. After cell culture, the cells are lysed to release iATP, which reacts with a luciferin/luciferase reagent to produce bioluminescence. This is detected as light in a luminescence plate reader. The assay does not incorporate methylcellulose and therefore is not a clonal assay. Instead, cells are grown and expanded in suspension that not only allows increased accuracy and sensitivity, but more rapid assay completion. Although the assay can be performed in just 5 days with high cell concentrations (2,500, 5,000 and 7,500 cells/well), a more optimal 7 day incubation time period using lower cell concentrations (1,000, 2,000 and 4,000 cells/well) was used in the majority of experiments described. As shown, this extra 2-day incubation produces an approximate 2–3 fold increase in ATP concentrations and therefore a concomitant increase in assay sensitivity.
Prior to measuring any samples, the ATP bioluminescence stem cell proliferation assay was calibrated using ATP calibrators and standardized using an external ATP standard curve. This allowed the non-standardized readout in relative luminescence units (RLU) to be interpolated as standardized ATP concentrations (μM). The ATP standard curve is a series of five ATP dilutions (from 0.01 μM to 1 μM) that produces a straight-line curve that can be fitted by linear regression analysis. The slope of the line must lie within specific upper and lower limits. The ATP calibrators are known ATP concentrations that must lie on the ATP standard curve and also produce values within specific upper and lower limits. When these conditions have been met, not only has an internal proficiency test been performed to ensure that the assay is working correctly, but also allows results from different experiments to be directly compared without normalization. In addition, the inclusion of these steps allowed the assay to be validated [31,32] according to regulatory guidelines .
All studies of UCB cell proliferation measured two stem cell populations. Since the ATP proliferation assays were methylcellulose-free and therefore not clonal, the first stem cell population was the equivalent to, and designated as, CFC-GEMM, using exactly the same growth factor cocktail as described for the CFU assay. The second was the more primitive lympho-hematopoietic high proliferative potential – stem and progenitor cell (HPP-SP), which included, interleukins 2 and 7 (Il-2, IL-7). For these studies, all growth factors and cytokines were obtained from CellGenix (Freiburg, Germany) and EPO was obtained from Cell Sciences (Canton, MA, USA). For both of the stem cell populations, two parameters of cell proliferation were measured simultaneously. The first was proliferation ability or status. It determines the amount of cell proliferation at a specific cell dose and point in time. The second parameter was proliferation potential, which is measured by the slope of the cell dose response linear regression . The more primitive a stem cell population the greater the slope of the cell dose response and therefore the greater the proliferation potential of the stem cell. Measuring stem cell proliferation potential is also the basis for measuring stem cell potency [31,32,35-37].
Based on historical UCB sample data [32,35], a power calculation was used to determine a minimum sample size needed for the present studies (Systat Software, Version 13.1, San Jose, CA). For a power of 0.9, a total of 11 samples were required to reject our “null hypothesis”. In fact, a total of 63 individual cord blood segments obtained from two different cord blood banks were tested. Studies were initiated on 22 segment samples cultured for 5 days at high cell concentrations. The remaining 41 segments were tested at lower cell concentrations for 7 days. The standardized ATP assay allowed all of the results to be compared directly. In addition, several of the segments were provided in duplicate allowing a comparison not only between individual segments from the same lot (unit), but also to determine if differences might be due to methodological changes performed by the investigators. To determine if methodology might be a contributing factor to differences observed between segments, a Bland-Altman statistic was used. For the CFU assay, each data point was performed in quadruplicate and results calculated as the mean ± standard deviation. For the ATP proliferation assay, 8 replicates were performed for each data point. All of the results from these assays are based on raw data and are expressed as the mean ± standard deviation (SD) or standard error of the mean (SEM), where appropriate. In addition, the percent coefficients of variation (%CV) were also evaluated. To determine the slope of the cell dose response, linear regression analysis was performed given by parameter B in the equation Y = A + Bx, where A is the intercept with the ×-axis. For linear regression analysis, the slope and the correlation coefficient (r) were calculated. The goodness of fit (R2) was omitted since this can be calculated from the square root of the correlation coefficient. For all results demonstrating cell proliferation, the historical acceptance/rejection limit was 0.04 μM ATP ± 15%. This is provided in all applicable graphs. Cells exhibiting ATP values greater than 0.04 μM are usually capable of sustaining proliferation. Cell exhibiting ATP values within or just below the acceptance/rejection level will have limited proliferation capability, while cells showing ATP values of 0.01 μM or less will be metabolically dead and will not proliferate. Depending on whether a comparison was made between two groups or multiple groups, a two-tailed t-test or two-way analysis of variance (ANOVA) was performed, respectively. This and all other statistical analyses, with the exception of power analysis, used GraphPad Prism software (version 6f for Mac).
Cord blood component parameters before and after fractionation
Combined percent reduction of mature blood components between TNC and MNC fractions for 56 segment samples
Segment cell composition
TNC fraction (Mean ± St.Dev)
MNC fraction (Mean ± St.Dev)
Percent reduction (Mean ± St.Dev)
RBCs (× 1012/L)
0.74 ± 0.19
0.19 ± 0.09
74.32 ± 16.75
12.21 ± 0.034
1.52 ± 0.02
87.55 ± 20.45
Platelets (× 109/L)
258.84 ± 124.04
15.34 ± 14.79
94.07 ± 5.25
White blood cells (× 109/L)
20.04 ± 7.48
2.44 ± 3.00
87.82 ± 12.26
Granulocytes (× 109/L)
2.30 ± 1.22
0.11 ± 0.03
95.22 ± 1.28
Lymphocytes (× 109/L)
14.64 ± 5.51
1.72 ± 1.16
88.25 ± 10.34
95.80 ± 1.13
99.76 ± 0.07
The CFU differentiation assay and correlation with the ATP proliferation assay
In parallel with the CFU assay, the same investigators using the same cell preparations and dilutions also prepared an ATP proliferation assay. The cells were cultured for 7 days and the ATP concentrations measured after the assay had been calibrated and standardized as described in the Method section. Figure 1B shows how the total colony counts from the CFU assay correlate directly with ATP concentration values. Like the results from the CFU assay, not only were the correlation coefficients of the cell dose response linear regressions high, but the cord blood TNC fraction produced lower ATP concentrations with a concomitant lower slope for the linear regressions than the MNC fraction. Lower colony counts combined with a decreased slope for the cell dose response, indicated that the TNC fraction affects assay sensitivity caused by other cell impurities. This implies that the lower stem cell response from a TNC fraction might not allow high-quality UCB units to be saved for patient use.
Calculation of total primitive hematopoietic stem cell (CFC-GEMM) activity based on the number of colonies and ATP concentrations at 2,500 cells
CFC-GEMM at 1 × 10 5 cells
Colony number in TNC fraction
800 ± 242
37,840 ± 11,424
Colony number in MNC fraction
3,175 ± 300
49,085 ± 4,279
ATP (μM) in TNC fraction
8.8 ± 2.6
416 ± 125
ATP (μM)in MNC fraction
35.4 ± 3.3
673 ± 47
The effect of cell dose and incubation time on the cord blood stem cell response
The results demonstrate that low cell doses combined with a longer incubation time of 7 days produce a more sensitive assay than higher cell doses cultured for only 5 days. For both the TNC and MNC fractions, the HPP-SP exhibits a steeper slope than that for CFC-GEMM, indicating that the former has a greater proliferation potential, is more primitive and therefore more potent than the latter stem cell population. More important, however, is the observation that the TNC fraction produces “stunted” proliferation for both stem cell populations compared to the MNC fraction (cf Figure 1). This effect is directly related to “masking” of the rare stem cell populations by other cell impurities in TNC fraction.
Mean coefficients of variation for stem cell populations derived from TNC and MNC fractions tested at low cell doses (1,000, 2,000 and 4,000 cells/well) for 7 days
Cell concentration / well
Comparison between segments from the same lot
The only groups that were statistically different within the TNC set of samples were the HPP-SP stem cell population in both segments 1 (P = 0.003) and 2 (P = 0.013). The lack of statistical difference between segments 1 and 2 within the TNC set is due to the low ATP concentrations and the high variances produced by this set of data. All the MNC data demonstrated greater ATP concentrations than the TNC data and therefore significant differences were seen for both segments 1 and 2 at the 2,000 and 4,000 cell/well levels for both stem cell populations. Also noteworthy was the observation that when linear regression curves were fitted to the TNC data from segments 1 and 2 for each of the stem cell populations, the results showed either no correlation or a negative correlation, thereby indicating a difference between the segments of the same unit (data not shown) .
The relationship between cord blood segment and unit
Usually, between two and four contiguous segments are produced and cryopreserved with the UCB unit. One or more of the segments are used primarily for HLA confirmatory testing, but if sufficient cells are available, viability, CD34 and even a CFU assay may also be performed. The object is to confirm that the cells in the segment represent those in the unit and therefore should provide some assurance that the unit can be released and that the cells will perform as expected. Reports have shown that the segment is representative of the sample , but others have a shown a discrepancy with respect to the position of the segment in relation to the unit . To test whether the segment is a true representation of the UCB unit, several units with attached segments were examined in parallel. After thawing, an aliquot of the unseparated, TNC fraction was removed from both the segment and the unit. A cell count, viability, and a 3-point cell dose response for CFC-GEMM determined by the CFU assay and CFC-GEMM and HPP-SP measured using ATP bioluminescence. The remaining cells from the segment were processed to a MNC fraction. All of the remaining cells from the unit were divided equally and also processed to a MNC fraction, but by different investigators.
Comparison of differential counts for the unit and segments post-thaw, unseparated, TNC and separated, MNC fractions
Segment cell composition
TNC fraction unit (Mean ± St.Dev)
MNC fraction unit (Mean ± St.Dev)
TNC fraction segment (Mean ± St.Dev)
MNC fraction segment (Mean ± St.Dev)
RBCs (× 1012/L)
1.64 ± 0.5
0.5 ± 0.42
0.94 ± 0.3
0.7 ± 0.4
28.5 ± 9.2
9.0 ± 4.8
15.5 ± 1.0
8.9 ± 6.4
Platelets (× 109/L)
279.0 ± 67.9
35.8 ± 34.4
183 ± 16.3
46.3 ± 6.7
White blood cells (× 109/L)
20.6 ± 6.0
2.5 ± 2.7
12.1 ± 3.3
3.1 ± 0.3
Granulocytes (× 109/L)
12.6 ± 4.5
0.1 ± 0.14
1.0 ± 0.2
0.1 ± 0.05
Lymphocytes (× 109/L)
15.5 ± 1.8
2.4 ± 0.5
9.2 ± 2.6
2.8 ± 0.3
Calculation of total stem cell activity between the umbilical cord blood segment and unit based on the number of colonies and ATP concentrations at 2,000 cells/well
CFC-GEMM at 1 × 10 5 cells
HPP-SP at 1 × 10 5 cells
Colonies – TNC Segment
475 ± 96
6,835 ± 1,374
2,275 ± 433
13,533 ± 2,005
Colonies – TNC Unit
487.5 ± 165
8,141 ± 2,759
Colonies – MNC Unit
2,400 ± 248
23,624 ± 1,617
ATP Bioluminescence Proliferation Assay
CFC-GEMM at 1 × 105 cells
HPP-SP at 1 × 105 cells
Total CFC-GEMM in the Unit
Total HPP-SP in the Unit
ATP (μM) - TNC Segment
22.0 ± 15.1
24.1 ± 20.0
317 ± 217
347 ± 288
ATP (μM) – MNC Segment
58.5 ± 6.5
73.8 ± 2.4
494 ± 44
597 ± 16
ATP (μM) – TNC Unit
29.0 ± 8.6
33.9 ± 11.1
8,732 ± 2,572
10,180 ± 3,335
ATP (μM) – MNC Unit
88.2 ± 11.9
107.2 ± 11.5
13,679 ± 1,440
17,991 ± 1,396
Table 5 shows the calculated colony number and ATP concentrations for the two stem cell populations detected in the TNC and MNC fractions of both the segments and unit. CFU colony counts based on 1 × 105 cells were not significantly different between the TNC segment and unit (P > 0.05) and MNC segment and unit (P > 0.05). Based on the CFU output, this might imply that the segment represented the unit. However, the calculated total CFC-GEMM content for the MNC fraction does not confirm this. When the proliferation ability of the stem cells was examined based on 1 × 105 cells, the TNC fractions in the segments and unit were also similar, but the values for the MNC fractions were significantly different between the segment and unit for both stem cell populations. These differences were also observed when total UCB unit values were calculated. These results illustrate the need for caution in assuming that the segment is a true representation of the unit.
Comparison between umbilical cord blood samples from two cord blood banks
Comparison between umbilical cord blood samples from two cord blood banks
Cord Blood Bank 1 (N = 12)
Cord Blood Bank 2 (N = 29)
TNC (mean ± SEM %CV)
MNC (mean ± SEM %CV)
TNC (mean ± SEM %CV)
MNC (mean ± SEM %CV)
0.09 ± 0.03, 91.9%
0.238 ± 0.06, 64.5%
0.057 ± 0.01 91.7%
0.122 ± 0.01, 60.6%
0.099 ± 0.03, 99.7%
0.323 ± 0.06, 56.5%
0.06 ± 0.01, 90.3%
0.146 ± 0.02, 58.7%
0.165 ± 0.04, 74.2%
0.544 ± 0.1, 57.6% 
0.085 ± 0.01, 86.3%
0.25 ± 0.02, 46.1% 
0.21 ± 0.06, 79.6%
0.723 ± 0.13, 56.2% 
0.126 ± 0.03, 111.0%
0.308 ± 0.03, 79.7% 
0.284 ± 0.08, 87.4%
0.887 ± 0.16, 58.2% 
0.177 ± 0.03, 81.9%
0.499 ± 0.05, 49.0% 
0.396 ± 0.1, 73.0%
1.352 ± 0.2, 47.4% 
0.293 ± 0.05, 87.8%
0.704 ± 0.06, 45.9% 
The relationship between viability and ATP bioluminescence
The results presented in this communication demonstrate that rare stem cell populations can be detected and quantitatively measured in very small volumes of UCB sample segments. The results also show that UCB cell preparation purity and viability can have a significant influence on detecting specific cell populations as well as how they are measured. Compared to the MNC fraction, the cell impurities in the TNC fraction are not only responsible for producing high variability, but also masking the presence of the rare stem cells populations. This, in turn, significantly underestimates, both the quality and potency of the stem cells in the UCB segment and unit. The TNC fraction is considered one of the basic parameters upon which several important assumptions are made, including whether the unit will be stored for transplantation purposes and uploaded to a cord blood inventory, the quality of the unit, its release for transplantation purposes and correlation with clinical outcome . The present results not only call into question the use of pre-freeze testing to represent the post-thaw unit, but many of the assumptions regarding how the quality and potency of a cord blood unit can be determined prior to transplantation.
The ATP bioluminescence signal detection system is the most sensitive, non-radioactive readout available for cell viability and function . Previous studies had demonstrated the correlation between CFU colony counts and the measurement of iATP as a biochemical marker for hematopoietic cell proliferation . The present results again demonstrate this correlation for UCB stem cells not only in sample segments, but also in the whole unit. This verification of one assay against the other substantiated the use of the ATP bioluminescence, CFU-alternative assay to perform this study. That the ATP bioluminescence stem cell proliferation assay is calibrated and standardized, thereby providing an internal proficiency test every time samples are processed, and has been validated according to regulatory guidelines , lends further credibility to the results.
Cell viability and nucleated cell counts are two of the most basic laboratory parameters required to perform most cell-based assays. Dye exclusion methods such as trypan blue, propidium iodide, acridine orange and 7-AAD are regularly used to measure cell viability for many applications. The use of 7-AAD is usually combined with the measurement of CD34 by flow cytometry to determine the number of viable CD34+ cells in the UCB segment and/or unit [44,45]. It has always been assumed that dye exclusion viability provides a rapid and reliable measure of live/dead cells in the suspension. The possibility that a viability measurement may produce false positive results is of particular concern, since this has many serious repercussions. These include the decision to permanently store a UCB unit, add it to a cord blood inventory, and use the unit for transplantation purposes.
The TNC count has been used in hematopoietic cell transplantation for decades. By definition, the TNC fraction contains virtually all nucleated cells, including granulocytes, as well as varying concentrations of platelets, red blood cells and other cell types. Many of these are lysed or killed during the cryopreservation process. It is not known whether stem cells undergo the same fate. Nevertheless, the post-freeze TNC fraction still contains high levels of cell impurities. These impurities do not contribute to the engraftment process and, as demonstrated in both the segment and unit, actually hinder the detection of the stem cells responsible for engraftment by diluting and “masking” their presence. This effect has also been observed using the CFU assay . Although density gradient centrifugation is a simple and rapid purification step from the TNC to MNC fraction and was perfectly suitable to test the hypothesis proposed for these studies, it is certainly not optimal for the rapid and cost-effective processing of large numbers of UCB units. Automated, “closed” systems have been available to further purify the cells in UCB units for some time [22,24], but are rarely used, since cord blood banks normally perform plasma and red blood cell reduction. It would appear that storing UCB units as MNC fractions instead of TNC fractions would provide more accurate and reliable results that would be more relevant to the transplant physician, since at the very least, it affects both the “quality” and potency of the UCB unit.
What constitutes a high-quality, and high potency UCB unit, is still a matter of debate [46-48]. The non-binding recommendations of the FDA  provide values for the minimum TNC, viability and viable CD34+ content as measures of purity and potency. For processing, a UCB unit usually requires a TNC count of at least 1 × 109 cells , with UCB units containing greater than 1.79 × 109 TNC being preferred by transplantation centers [26,51]. As demonstrated here, increased cell dose correlates with increased ability to detect and measure stem cell proliferation in the unit. Therefore, the higher the TNC count, the greater the proportion of stem cells in the unit and the higher the probability of engraftment. This is because engraftment is dependent upon the ability of the stem cells to proliferate. If stem cell proliferation cannot be adequately measured because impurities in the TNC fraction mask, impair and underestimate their functionality, then the quality of the UCB unit cannot be accurately and reliably determined. By definition, the CFU-GEMM stem cell population is characterized by the presence of granulocytes and macrophages, erythroid cells and megakaryocytes within a single colony. The identification of these cell types by flow cytometry after stimulation of the CFC-GEMM population in an ATP bioluminescence assay was demonstrated previously . However, most methylcellulose formulations do not contain TPO required to potentiate stem cells and stimulate megakaryopoiesis. As a result, the population actually detected by this reagent is more mature and therefore correlates to a greater degree with CD34 and GM-CFC , than that detected in the present studies. For normal UCB testing, the CFU assay is used primarily to determine the presence of granulocyte-macrophage (GM) progenitor cells as a predictor of granulocyte neutrophil production and an indicator of time to neutrophil engraftment . Since this is part of the early reconstitution process and downstream from stem cell engraftment, detection of GM-progenitor cell growth neither predicts nor determines the potential of the stem cells for engraftment . Even though determination of CD34 membrane expression is considered a “stem cell marker”, it is far from specific , and provides no information on stem cell functionality. The CD34 marker was not determined in these studies because (a), it would have depleted cell numbers for measuring cell proliferation, and (b), previous studies had shown that CD34 did not correlate with ATP, since it is not a stem cell marker [32,35]. Taken together, it is necessary to seriously question the notion that a UCB unit can be of high-quality and potency when (a) the sample being tested is impure, and (b), that the presence and functional properties of stem cells in the product are not detected and measured to predict engraftment potential.
Throughout these studies, a minimum 3-point cell dose response was performed for all segments and units tested. This allowed two parameters of stem cell proliferation to be determined simultaneously. The first was the ability of the stem cells to proliferate at a specific cell dose, and at the time the sample was thawed. This parameter is proliferation ability or status and is equivalent to stem cell “quality”. The second is proliferation potential, a key property of stem cell primitiveness, and determined from the slope of the stem cell dose response linear regression . The steeper the slope of the cell dose response, the more primitive the stem cell population. As shown, the HPP-SP is more primitive than the CFC-GEMM stem cell population. However, proliferation potential correlates with several other parameters. These include stem cell self-renewal capacity and engraftment potential. These parameters are, in turn, directly related to the potency of the stem cell population; the more primitive a stem cell population, the greater its proliferation potential and potency and, therefore, its engraftment potential. It has been shown previously that proliferation potential is a requirement for measuring the potency of the “active” stem cell components [31,32,35-37]. The present results clearly demonstrate that measuring UCB stem cell proliferation is also a requirement if accurate and reliable information is to be accrued and used in the cord blood inventories.
The TNC count, viability, viable CD34+ count and the total number of colonies or number of GM colonies have been used for decades to characterize UCB samples and equate the results to the unit. This was the reason for hypothesizing that using the TNC fraction from UCB segments and units did not have to be further purified in order to accurately, reliably and reproducibly measure the stem cells. The data presented above clearly reject this hypothesis. Cord blood segments and units that contain varying degrees of cell impurities cannot be used to determine UCB stem cell quality or potency. It might be argued that since hematopoietic stem cell transplantation has been a routine procedure for decades using essentially the same tests and assays, there is no reason to characterize and measure the stem cells prior to infusion into the patient. However, it is now obvious that several basic assumptions upon which UCB transplantation have been based, have now been called into question. Umbilical cord blood transplantation continues to deal with long engraftment times (usually 20–25 days) [8-10], and a high rate of graft failure (20-24%) [8,10,52], both of which are detrimental to the patient. Umbilical cord blood is being used for numerous clinical applications and virtually all use the same basic tests and assays and therefore the same basic assumptions. As argued by other authors [27,28], improvements can and should be made. The present data clearly substantiates those arguments, but also provides simple and substantive methods for improvement that might help reduce engraftment times, graft failure, and ultimately benefit the patient.
According to the NMDP , more than 25,000 cord blood unit stem cell transplants have been performed worldwide. All have been characterized using TNC, viability, viable CD34 content and the CFU assay, but virtually none have been analyzed to ensure that the stem cells responsible for engraftment exhibit high functional quality and potency. Using a highly sensitive and standardized ATP bioluminescence stem cell proliferation assay, it is shown that the TNC fraction, upon which many of the decisions are made, from cord blood storage to release of a unit for transplantation purposes, not only dilute and mask the stem cells responsible for engraftment, but can underestimate the quality and potency of the UCB unit. The results call into question many of the premises that are being used in cord blood banking and processing. These include differences between individual cord blood sample segments prepared at the time the unit is processed and used for confirmatory testing, assuming the segment is a true representation of the cord blood unit and high false positive viability values that do not correlate with the metabolic viability and functionality of the stem cells in the segment or unit. The results demonstrate that the more purified MNC fraction will provide more precise and accurate measurements of stem cell properties that can be used to better define the quality and potency of the cord blood unit prior to use. Indeed, the results imply that cord blood units should be stored as MNC rather than TNC preparations. In addition, although testing must be performed on the pre-freeze unit to determine stem cell suitability for storage and later use, specific stem cell quality and potency determinations should be performed, and the information uploaded to cord blood inventories, on samples of cells shortly after cryopreservation. This would provide more relevant details on the stem cell status that better represent the unit when it is eventually selected by a transplantation center to treat a patient.
This work was funded solely by HemoGenix.
- Messner HA, Fauser AA, Lepine J, Martin M. Properties of human pluripotent hematopoietic progenitors. Blood Cells. 1980;6:595–607.PubMedGoogle Scholar
- Hodgson GS, Bradley TR, Radley JM. The organization of hematopoietic tissue as inferred from the effects of 5-fluoruracil. Exp Hemat. 1982;10:26–35.PubMedGoogle Scholar
- Johnson GR. Methodology for the identification and characterization of hematopoietic cells. Clonal assays for multipotential hematopoietic cells in vitro. Bibl Haematol. 1984;48:63–80.PubMedGoogle Scholar
- Bradley TR, Hodgson GS, Bertoncello I. High proliferative potential colony forming cells. Methods Mol Biol. 1990;5:289–97.PubMedGoogle Scholar
- Stephenson JR, Axelrad AA, McLeod DL, Shreeve MM. Induction of colonies of hemoglobin-synthesizing cells by erythropoietin in vitro. Proc Natl Acad Sci USA. 1971;68:1542–6.View ArticlePubMed CentralPubMedGoogle Scholar
- Iscove NN, Sieber F, Winterhalter KH. Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A. J Cell Physiol. 1974;83:309–20.View ArticlePubMedGoogle Scholar
- Cottler-Fox M. Hematopoietic progenitor cells. In: Burt RK, Deeg HJ, Lothian ST, Santos GW, editors. On Call in … Bone Marrow Transplantation. London, UK: Chapman and Hall; 1996. p. 69–75.Google Scholar
- Broxmeyer HE. Cord blood hematopoietic stem cell transplantation. In: StemBook.org. Cambridge, MA: Harvard Stem Cell Institute; 2010.Google Scholar
- Ruggeri A, Labopin M, Sormani MP, Sanz G, Sanz J, Volt F, et al. Engraftment kinetics and graft failure after single umbilical cord blood transplantation using myeloablative conditioning regimen. Haematologica. 2014;99:1509–15. doi:10.3324/haematol.2014.View ArticlePubMedGoogle Scholar
- Page KM, Xhang L, Mendizabal A, Wease S, Carter S, Gentry T, et al. Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single center analysis of 435 cord blood transplants. Biol Blood Marrow Transplant. 2011;17:1362–74. doi:10.1016/j.bbmt.2011.01.011.View ArticlePubMedGoogle Scholar
- Sutherland DR, Keating A, Nayar R, Anania S, Stewart AK. Sensitive detection and enumeration of CD34+ cells in peripheral and cord blood by flow cytometry. Exp Hematol. 1994;22:1003–10.PubMedGoogle Scholar
- Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321:1174–8.View ArticlePubMedGoogle Scholar
- Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci. 1966;44:287–99.View ArticlePubMedGoogle Scholar
- Pluznik DH, Sachs L. The induction of clones of normal mast cells by a substance from conditioned medium. Exp Cell Res. 1966;43:553–63.View ArticlePubMedGoogle Scholar
- Pike BL, Robinson WA. Human bone marrow colony growth in agar-gel. J Cell Physiol. 1970;76:77–84.View ArticlePubMedGoogle Scholar
- Kriegler AB, Bradley TR, Hodgson GS, McNiece IK. A colorimetric liquid culture assays of a growth factor for primitive murine macrophage progenitor cells. J Immunol Meth. 1987;103:93–102.View ArticleGoogle Scholar
- Monner DA. An assay for growth of mouse bone marrow cells in microtiter liquid culture using the tetrazolium salt MTT, and its application to studies of myelopoiesis. Immunol Lett. 1988;19:261–8.View ArticlePubMedGoogle Scholar
- Horowitz D, King AG. Colorimetric determination of inhibition of hematopoietic progenitor cells in soft agar. J Immunol Meth. 2000;244:49–58.View ArticleGoogle Scholar
- Rich IN, Hall KM. Validation and development of a predictive paradigm for hemotoxicity using a multifunctional bioluminescence colony-forming proliferation assay. Tox Sci. 2005;87:427–41.View ArticleGoogle Scholar
- Reems J-A, Hall KM, Gebru LH, Taber G, Rich IN. Development of a novel assay to evaluate the functional potential of umbilical cord blood progenitors. Transfusion. 2008;48:620–8.View ArticlePubMedGoogle Scholar
- Crouch SP, Kozlowski R, Slater KJ, Fletcher J. The use of ATP bioluminescence s a measure of cell proliferation and cytotoxicity. J Immunol Meth. 1993;160:81–8.View ArticleGoogle Scholar
- Solves P, Planelles D, Mirabet V, Blanquer A, Carbonell-Uberos F. Qualitative and quantitative cell recovery in umbilical cord blood processed by two automated devices in routine cord blood banking: a comparative study. Blood Transfus. 2013;11:405–11.PubMed CentralPubMedGoogle Scholar
- Harris DT. Collection, processing, and banking of umbilical cord blood stem cells for clinical use in transplantation and regenerative medicine. Labmedicine. 2008;39:173–8. doi:10.1309/64QG394K1M639L8A.Google Scholar
- Basford C, Forraz N, Habibollah S, Hanger K, McGuckin C. The cord blood separation league table: a comparison of major clinical grade harvesting techniques for cord blood stem cells. Intl J Stem Cell. 2010;3:32–45.View ArticleGoogle Scholar
- Aroviita PI, Teramo K, Westman P, Hiilesmaa V, Kekomaki R. Associations among nucleated cell, CD34+ cell and colony-forming cell contents in cord blood units obtained through a standardized banking process. Vox Sang. 2003;84:219–27.View ArticlePubMedGoogle Scholar
- George TJ, Sugrue MW, George SN, Wingard JR. Factors associated with parameters of engraftment potential of umbilical cord blood. Transfusion. 2006;46:1803–12.View ArticlePubMedGoogle Scholar
- Spellman S, Hurley CK, Brady C, Phillips-Johnson L, Chow R, Laughlin M, et al. Guidelines for the development and validation of new potency assays for the evaluation of umbilical cord blood. National Marrow Donor Program Advisory Group. Cytotherapy. 2011;13:848–55.View ArticlePubMedGoogle Scholar
- Pamphillon D, Selogie E, McMenna D, Cancelas-Peres JA, Szczepiorkowski ZM, Cacher R, et al. Current practices and prospects for standardization of the hematopoietic colony-forming unit assay: a report by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Cytotherapy. 2013;15:255–62.View ArticleGoogle Scholar
- Rich IN, Kubanek B. The effect of reduced oxygen tension on colony formation of erythropoietic cells in vitro. Brit J Haematol. 1982;52:579–88.View ArticleGoogle Scholar
- Olaharski AJ, Uppal H, Cooper M, Platz S, Zabka TS, Kolaja KL. In vitro to in vivo concordance of a high throughput assay for bone marrow toxicity across a diverse set of drug candidates. Toxicol Let. 2009;188:98–103.View ArticleGoogle Scholar
- Hall KM, Rich IN. Bioluminescence assays for assessing potency of cellular therapeutic products. In: Areman EM, Loper K, editors. Cellular therapy: principles, methods and regulations. Bethesda, MD: AABB. ISBN 978-1-56395-296-8; 2009. p. 581–91.Google Scholar
- Hall KM, Harper H, Rich IN. Hematopoietic stem cell potency for cellular therapeutic transplantation, advances in hematopoietic stem cell research. Rosana Pelayo (Ed.), 2012, 383–406. ISBN: 978-953-307-930-1, InTech, Available from: http://www.intechopen.com/books/advances-in-hematopoietic-stem-cell-research/hematopoietic-stem-cell-potency-for-cellular-therapeutic-transplantation.
- U.S. Food and Drug Administration (FDA). Guidance for Industry. Bioanalytical method validation. (2001). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.
- Rich IN. Measurement of hematopoietic stem cell proliferation, self-renewal, and expansion potential. In: Rich IN, editor. Stem Cell Protocols, Methods Mol Biol, vol. 1235. 2015. p. 7–17. doi:10.1007/978-1-4939-1785-3_4.View ArticleGoogle Scholar
- Rich IN. Potency, proliferation and engraftment potential of stem cell therapeutics: The relationship between potency and clinical outcome for hematopoietic stem cell products. J Cell Sci Ther. 2013. http://dx.doi.org/10.4172/2157-7013.S13-001.
- Harper H, Rich IN. Measure the potency of a stem cell therapeutic. In Stem Cell Protocols, Methods Mol Biol. Edited by Rich IN. 2015, 1235:33–48. doi:10.1007/978-1-4939-1785-3_4.Google Scholar
- Rich IN. Tissue engineering: Propagation and Potency Evaluation. In: Translational Regenerative Medicine, (Ed) Atala A. (2015) Elsevier. http://dx.doi.org/10.1016/B978-0-12-410396-2.00010-4.
- Gutensohn K, Odendahl M, Kersten JF, Tonn T. Validation of cord blood split products prepared by an automated method. Transfus Med. 2013;23:48–51.View ArticlePubMedGoogle Scholar
- Rodriguez L, Garcia J, Querol S. Predictive utility of the attached segment in the quality control of a cord blood graft. Bio Blood Marrow Transplant. 2005;11:247–51.View ArticleGoogle Scholar
- De Vos J, Birebent B, Faucher C, Giet O, Hicheri Y, Lemarie C, et al. Quality controls on cord blood unit contiguous segments: Recommendation of the SFGM-TC. Path Biol. 2014;62:218–20.View ArticleGoogle Scholar
- Barker JN, Bya C, Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood. 2011;117:2332–9.View ArticlePubMed CentralPubMedGoogle Scholar
- Zumpe C, Bachmann CL, Metzger AU, Wiedermann N. Comparison of potency assays using different read-out systems and their suitability for quality control. J Immunol Meth. 2010;360:129–40.View ArticleGoogle Scholar
- Rich IN. In vitro hematotoxicity testing in drug development: a review of past, present and future applications. Curr Opinion in Drug Disc Develop. 2003;6:100–9.Google Scholar
- Pretti RA, Chan WS, Kurtzburg J, Dornsife RE, Wallace PK, Furlage R, et al. Multi-site evaluation of the BD stem cell enumeration kit for CD34+ cell enumeration on the BD FACSCanta II and BD FACSCalibur flow cytometers. Cytotherapy. 2014;16:1558–74.View ArticleGoogle Scholar
- Pope B, Hokin B, Grant R. Effect of umbilical cord blood prefreeze variables on postthaw viability. Transfusion 2014, doi:10.1111/trf.12873.Google Scholar
- Salge-Bartels U, Huber HM, Kleiner K, Volkers P, Seitz R, Heiden M. Evaluation of quality parameters for cord blood donations. Transf Med Hemother. 2009;36:317–24.View ArticleGoogle Scholar
- Scaradavou A, Smith KM, Hawke R, Schaible A, Abboud M, Kerman NA, et al. Cord blood units with low CD34+ cell viability have a low probability of engraftment after double unit transplantation. Biol Blood Marrow Transplant. 2010;16:500–8.View ArticlePubMedGoogle Scholar
- Querol S, Gomez SG, Pagliuca A, Torrabadella M, Madrigal JA. Quality rather than quantity: the cord blood bank dilemma. Bone Marrow Transplant. 2010;50:265.Google Scholar
- U.S. Food and Drug Administration (FDA). Guidance for Industry. Biologics license applications for minimally manipulated unrelated allogeneic placenta/umbilical cord blood intended for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system. (2014). http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM357135.pdf.
- Page KM, Mendizabal A, Betz-Stablein B, Wease S, Shoulars K, Gentry T, et al. Optimizing donor selection for public cord blood banking: influence of maternal, infant, and collection characteristics on cord blood quality. Transfusion. 2014;54:340–52.PubMed CentralPubMedGoogle Scholar
- Bart T, Boo M, Balabanova S, Fisher Y, Nicolosco G, Foeken L, et al. Selection and sustainability: impact on selection of the cord blood units from the United States and Swiss registries on the cost of banking operations. Transfus Med Hemother. 2013;40:14–20.View ArticlePubMed CentralPubMedGoogle Scholar
- Allen D, Petraszko T, Elmoazzan H, Smith S. A review of factors influencing the banking of collected umbilical cord blood units. Stem Cell International 2013, http://dx.doi.org/10.1155/2013/463031.
- National Marrow Donor Program (NMDP). http://bethematch.org/transplant-basics/cord-blood-and-transplants.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.